CCCC — C4 Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.86
-$0.01 (-0.26%)
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on NASDAQ. It is led by Andrew J. Hirsch M.B.A., based in 490 Arsenal Way, Watertown, MA, United States, 02472, with about 104 employees. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest reported CCCC revenue for 2025-09-30 was $11.2M. Net income was -$84.5M. Revenue was up 73.8% from 2025-06-30 to 2025-09-30. CCCC currently screens at market cap $425.7M.
Use this CCCC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CCCC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CCCC SEC filings page. Lician reads the product cache first so this HTML stays unique to C4 Therapeutics Inc even when a live quote feed is slow.
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Key Statistics
Market Cap
$425.68M
Volume
2.34M
Previous Close
$4.10
Day Range
$4.10 – $4.24
EPS
-$1.52
Revenue
$35.58M
Net Income
-$105.32M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+71.4%
Profit Margin
-296.0%
Employees
104
CCCC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $35.58M | $20.76M | $31.10M | $45.78M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$105.32M | -$132.49M | -$128.18M | -$83.89M |
| EPS (Diluted) | -$1.52 | -$2.67 | -$2.62 | -$1.82 |
Total Assets
$349.60M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.50M
Operating Cash Flow
-$65.16M
Free Cash Flow
$0.00
C4 Therapeutics Inc Company Information
- CEO, President & Director
- Andrew J. Hirsch M.B.A.
- Headquarters
- 490 Arsenal Way, Watertown, MA, United States, 02472
- Website
- www.c4therapeutics.com
- Phone
- 617 231 0700
- IPO / Founded
- 2020-10-02
- Sector
- Healthcare
- Industry
- Biotechnology